Physician profile
Mike E Rodriguez
NPI 1306847504
$5,001.60
in general payments reported to CMS, 2019-2025
20 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,562 · 2020: $69.41 · 2021: $393 · 2022: $264 · 2023: $2,309 · 2024: $284 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Travel and Lodging: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.41 |
| Travel and Lodging | $1,333.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,799.31 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $1,126.66 | 2019-2020 | |
| Abiomed | $670.94 | 2019-2025 | Impella |
| Abbott Laboratories | $244.88 | 2019-2025 | Navitor |
| Janssen Pharmaceuticals, INC | $231.96 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $195.72 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $187.34 | 2019-2023 | |
| Medtronic USA, INC. | $125.44 | 2019 | |
| Pfizer INC. | $78.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $65.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $57.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $46.63 | 2023-2024 | |
| Medtronic, INC. | $37.13 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.52 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $22.02 | 2024 | Vabysmo |
| Spr Therapeutics, INC | $16.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.59 | 2023 | Eliquis |
| Lexicon Pharmaceuticals, INC. | $13.16 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $7.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mike Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.